TG Therapeutics, Inc. - רווח למניה בשנים עשר החודשים האחרונים TGTX

High FDA barriers and prolonged R&D create a robust defense for the profitability of TG Therapeutics, Inc. (TGTX). The net income per share trend illustrates the speed of the business recovery, where the 0.66 mark shows the current state. Growth is driven by Briumvi sales and expansion in Europe, while scaling revenue against fixed science costs creates powerful operating leverage for capitalization.
TG Therapeutics Corp (TGTX) - פילוחי מדדים ודוחות פיננסיים

For the innovative biotech TG Therapeutics, Inc. (TGTX), which develops breakthrough treatments for multiple sclerosis, this indicator reflects the actual efficiency of capitalization by distributing total net income per common share. By analyzing the net income per share over the last 12 months, an investor assesses the company's ability to generate profit without inflating its debt load, which confirms the sustainability of the business model and the long-term investment attractiveness of the asset.